Project Details
Description
Project Summary/ Abstract
Leprosy has plagued mankind throughout human history and still afflicts 2 to 3 million people in
Developing Countries. Although the leprosy bacillus was the first bacterium reported to be
associated with human disease, it has yet never been cultivated on artificial media. It can be
grown in the footpads of nude mice or systemically in nine-banded armadillos. With a generation
time of 14 days, testing drug regimens are performed by counting acid-fast bacilli which is
laborious and time-consuming. The comparison of the M. leprae DNA sequence to M.
tuberculosis suggests the inability to culture M. leprae on artificial media might result from the
inability to synthesize methionine, pantothenate and mycobactin. Using genetic tools, we have
developed for M. tuberculosis, we hypothesize M. leprae can be stably transformed with phage-
based integration proficient plasmids. We plan to incorporate a Bioluminescent Resonance
Energy Transfer (BRET)-Nanoluc and Near infra-red proteins into the plasmid to detect
transformants. Furthermore, we hypothesize that the transformation of M. leprae with the missing
methionine and pantothenate biosynthetic genes and the mycobactin transporters will enable M.
leprae to grow on artificial media. An M. leprae strain that glows would enhance drug
development and the ability to assess the immunological mechanisms that control M. leprae
infections. The genetic engineering of M. leprae to grow on artificial media would enhance our
understanding of evolutionary processes that lead to obligate intracellular parasitism.
Status | Finished |
---|---|
Effective start/end date | 5/20/22 → 4/30/23 |
Funding
- National Institute of Allergy and Infectious Diseases: $210,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.